Gate Bioscience just dropped a Series B that hits like a bassline you feel in your ribs. $65M, oversubscribed, led by Forbion with Eli Lilly stepping in as a new investor and doubling down after its earlier partnership move. Versant Ventures, Andreessen Horowitz Bio + Health, GV, and ARCH Venture Partners came back in like seasoned crate diggers who know exactly when a track is about to blow. You do not oversubscribe a round at this stage unless the science is so sharp it cuts through the noise on its own. Credit where it belongs: Jordi Mata Fink PhD, Pat Sharp PhD, and Raman Talwar built something that refuses to play inside the usual biotech boundaries.
The play here is almost mischievous. Every one of the 4,000+ extracellular proteins uses the same exit tunnel inside the cell. Gate Bioscience studied that biological traffic jam and decided to place a molecular bouncer at the door, the kind that only stops the troublemakers and lets the rest of the crowd flow. These Molecular Gates are oral small molecules that block disease causing proteins inside the cell before they ever get secreted. No injections, no antibody acrobatics, just a clean chemical move that forces the bad actors to get chewed up by the cell’s own cleanup crew. Then add the small-molecule advantage of crossing the blood-brain barrier, and suddenly neurological diseases that have been stuck behind a no-entry sign might finally have a way in.
The team behind this platform reads like someone assembled a biotech supergroup. Brian Cathers PhD guiding the science with the calm precision of someone who has seen drugs all the way through. Nina Oberbeck PhD translating biology into human-ready logic. David pushing discovery forward. Li dialing chemistry into weapons-grade clarity. Jim shaping nonclinical data that stands up anywhere. Vanessa Van Voorhis PhD stitching programs and alliances into momentum. Danielle L. Aubele turning medicinal chemistry into a craft. Nearly 49 experts now fuel a platform that has grown into a true drug discovery engine capable of hitting targets across inflammation, neurological disease, cancer, fibrosis, and more than 1,000 protein-driven conditions.
That July collaboration with Eli Lilly, worth up to $856M in upfronts, equity, milestones, and royalties, was the moment the industry realized this was not a niche mechanism. It was a lever. The kind of lever pharma reaches for when biology keeps saying no and they need someone willing to rethink the geometry. Bringing in Vanessa Carle PhD to the board signals that Forbion sees the scale of this thing and wants hands on the steering wheel.
Gate Bioscience now moves toward IND-enabling studies and into the clinic with a platform built for speed, precision, and repeatability. This round is not about valuation. It is about velocity. It is about a company that discovered the gate every protein uses and learned how to control who gets through.
Startups Startup Funding Venture Capital Series B Biotech Biotechnology Healthcare Health Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
